The effects of teneligliptin on cardiac function and endothelial function in patients with type 2 diabetes

The effects of teneligliptin on cardiac function and endothelial function in patients with type 2 diabetes - Efficacy of teneligliptin in patients with type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012120

Enrollment

Registered

2013-10-28

Start date

2013-10-28

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

teneligliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1)Type-1 diabetes, diabetes due to a pancreatic disorder, or secondary diabetes due to conditions such as Cushing's syndrome and acromegaly 2)Application of contraindications contained in the package insert 3)Heart failure (NYHA grade 3-4) 4)Patients prone to QT prolongation 5)Excessive alcohol consumption 6)Pregnant women, women suspected of being pregnant, or lactating women 7)History of myocardial infarction 8)The medication in the treatment of diabetes drugs not be used with insurance 9)Under administration of GLP-1 agonists

Design outcomes

Secondary

Measure	Time frame
Echocardiography, Endothelial function, Biomarker	—

Primary

Measure	Time frame
Change in Glycosylated hemoglobin (HbA1c) levels over 24 weeks	—

Countries

Japan

Contacts

Public ContactShigeru Toyoda

Dokkyo Medical University Department of Cardiovascular Medicine

s-toyoda@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026